Definitive Healthcare downgraded to Underweight from Equal Weight at Barclays

Barclays downgraded Definitive Healthcare (DH) to Underweight from Equal Weight with an unchanged price target of $4. Definitive has declining revenue in fiscal 2025, which is not characteristic of the software group, driven by increased churn with life sciences customers that has not improved, the analyst tells investors in a research note. The firm says the company’s changes to its sales force are being made to rectify declining customer count and weaker renewals, but notes the changes take time to implement and will likely take down margins.